A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa

1. Subject male or female
2. Age ≥ 12 years old
3. Subject has recessive (Severe, Intermediate, Inversa or Pruriginosa) or dominant (Intermediate or Pruriginosa) dystrophic epidermolysis bullosa, confirmed by skin immunomapping and/or molecular analysis (one or 2 COL7A1 mutation(s)), according to the last EB classification 4) Subject has at least a baseline pruritus score ≥ 4/10.

5) Subject agrees not to use any topical therapies other than the investigator approved (VYJUVEK gel is accepted if ongoing at the time of the study, excepted on the left leg) 6) A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies: 7) (a) Is not a Women of Childbearing Potential (WOCBP) OR 8) Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), preferably with low user dependency, during the study period until the end of her participation to the study. Effective method of birth control recommended by the Clinical Trials Facilitation and Coordination group are combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral or intravaginal or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral or injectable or implantable); intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion 9) Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair his evaluation or which exposes the subject to an unacceptable risk by study participation.

10) Subject is willing and able to follow all study instructions and to attend all study visits.

11) Subject is able to comprehend and willing to sign an Informed Consent and/or Assent Form.

12) Affiliation with a social security scheme.

Exclusion Criteria:

1. Subjects who are treated with DUPILUMAB or JAK inhibitor. A wash out of 2 months is mandatory to be included.
2. Subjects with uncontrolled asthma.

3. Medical History and Concurrent Diseases:

   1. Any major surgery within 8 weeks prior to Day 1, or any planned surgery for the first 28 weeks of the study
   2. Has donated blood >500mLwithin 4 weeks prior to Day1, or plans to donate blood during the course of the study
   3. Drug or alcohol abuse, as determined by the investigator, within 6 months prior to Day 1
   4. Medical marijuana or prescription marijuana taken for medicinal reasons
   5. Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, psychiatric, neurologic, immunologic, or local active infection/infectious illness) that, in the investigator's judgment or after consultation with the Medical Monitor or designee, will substantially increase the risk to the participant if he or she participates in the study
   6. Unstable cardiovascular disease, defined as a recent clinical cardiovascular event (eg, unstable angina, myocardial infarction, stroke, rapid atrial fibrillation) in the last 3 months prior to screening, or a cardiac hospitalization (eg revascularization procedure, pacemaker implantation) within 3 months prior to screening, or patients at risk of major adverse cardiovascular events, deep venous thrombosis or pulmonary embolism.

   7. Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) >160 mm Hg or diastolic BP >100 mm Hg.

      Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the participant has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted.

   8. Class III or IV congestive heart failure by New York Heart Association Criteria
   9. Has cancer or history of cancer (solid organ or hematologic including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has been treated with no evidence of recurrence)
   10. Any significant/uncontrolled neuropsychiatric illness as clinically judged by the investigator during
4. Females of child-bearing potential who meet the following criteria for pregnancy testing:
5. Subjects with a positive serum pregnancy test at the Screening Visit or a positive urine pregnancy test at Baseline prior to the first dose of study treatment (local practices may require serum pregnancy testing at Baseline).
6. Subjects with a borderline serum pregnancy test at Screening must have absence of clinical suspicion of pregnancy or other pathological causes of borderline results and a serum pregnancy test ≥ 3 days later to document continued lack of a positive result (unless inclusion of subjects with a borderline pregnancy test may be prohibited by local requirements).
7. Subjects with a urine pregnancy test at Baseline that is borderline or ambiguous must have a serum pregnancy test performed. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
8. Female subjects of childbearing potential who are not able and/or willing to practice at least 1 protocol-specified method of birth control that is highly effective from Study Day 1 through at least 30 days after the last dose of study drug (local practices may require an additional method of contraception). Female subjects of non-childbearing potential do not need to use birth control.
9. Female subjects who are pregnant, breastfeeding, or considering becoming pregnant or donating eggs during the study and for 30 days after the last dose of study drug.
10. Subject has another member of her/his immediate family (i.e., living in the same household) enrolled in this study.
11. Subject has used any systemic product that, in the opinion of the investigator, might put the subject at undue risk by study participation or interferes with the study assessments within 30 days prior to Visit 1.
12. Vulnerable persons as mentioned in articles L1121-5, L1121-6, L1121-7, L1121-8 and L1122-1-2 of the public health code.
13. Subject has a history of sensitivity to any of the ingredients of Nemolizumab.
14. Withdrawal of the informed consent.